Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Biotechnology, Therapeutics

Headquarters

Winchester, United States

Employees

1-10

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

Bruce Weaver

VP of Manufacturing

Elena Ende

Finance Director

Steve Andress

Director of Legal

Teams

This company has no teams yet

Offices

Similar companies

Simcha Therapeutics

1 follower

Gilead Sciences

136 followers

Verily Life Sciences

38 followers

BioMarin Pharmaceutical

36 followers

Myriad Genetics

36 followers

Ultragenyx Pharmaceutical

10 followers

Sarepta Therapeutics

9 followers

Legend Biotech

9 followers

Neurocrine Biosciences

7 followers

Cepheid

7 followers

Halozyme Therapeutics

6 followers

Explore companies

��������